The largest project underway is Novo Nordisk’s $4.1 billion expansion ... Amgen is also growing its local footprint with a second drug substance manufacturing facility at its 109-acre campus ...

Once completed, the new facility will measure 833,000 square feet and have a footprint of 417,639 square feet ... The new facility will be adjacent to Novo Nordisk's 457,000-square-foot Clayton plant, ...

With nearly $14 billion in sales in 2023, it shows no signs of slowing down, much to the delight of its Danish manufacturer, Novo Nordisk A/S (NYSE: NVO). A Scandinavian economic behemoth ...

Novo Nordisk (NVO) is one of the stocks most watched by Zacks.com visitors lately. So, it might be a good idea to review some of the factors that might affect the near-term performance of the stock.

Novo Nordisk presents a compelling 'Strong Buy' opportunity with a 51% upside potential. NVO's financial strength is evident through its 74% historical average ROIC, 85% gross margin, and ...

That's the good news. The bad news is that the bloom may be coming off the GLP-1 rose, which is presumably the reason why not only Eli Lilly but Novo Nordisk and Viking Therapeutics stock are ...

Novo Nordisk (NYSE: NVO) has sparked investor interest primarily because of its weight loss treatments. Where to invest $1,000 right now? Our analyst team just revealed what they believe are the ...

Ozempic weight-loss drug maker Novo Nordisk on Wednesday expanded an existing agreement with a drug developer that uses artificial intelligence. Novo Nordisk said an agreement reached last year ...

Fintel reports that on January 8, 2025, UBS upgraded their outlook for Novo Nordisk A (NYSE:NVO) from Sell to Buy. As of December 23, 2024, the average one-year price target for Novo Nordisk A is ...